T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
Multiple myeloma: changes in serum C‐terminal telopeptide of collagen type I and bone‐specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*
TL;DR: Monitoring of bone disease in multiple myeloma is becoming increasingly important because bone‐protecting treatment with bisphosphonate is becoming restricted after the awareness of osteonecrosis of the jaw, and the potential of biochemical markers of bone remodeling to monitor dynamic bone turnover is investigated.
Journal ArticleDOI
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Nadine Kutsch,Jasmin Bahlo,Sandra Robrecht,Jeremy Franklin,Can Zhang,Christian Maurer,Nisha De Silva,Elisabeth Lange,R Weide,Michael G. Kiehl,Martin Sökler,Rudolf Schlag,Ursula Vehling-Kaiser,Georg Köchling,Christoph Plöger,Michael Gregor,Torben Plesner,Marco Herling,Kirsten Fischer,Hartmut Döhner,Michael Kneba,Clemens-Martin Wendtner,Wolfram Klapper,Karl-Anton Kreuzer,Sebastian Böttcher,Stephan Stilgenbauer,Anna-Maria Fink,Michael Hallek,Barbara Eichhorst +28 more
TL;DR: This research presents a novel probabilistic procedure called “spot-spot analysis” that allows for real-time analysis of the response of the immune system to foreign substance abuse.
Journal ArticleDOI
Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
TL;DR: In this article, four European experts provide their consolidated opinion on open questions surrounding the prophylactic use of IgRT in SID, based on their clinical experience, on the main topics are IgRT initiation, route of administration, dose optimization, and therapy discontinuation.
Journal ArticleDOI
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon,Gordon Cook,Saad Z. Usmani,Cyrille Hulin,Shaji Kumar,Torben Plesner,Cyrille Touzeau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Hartmut Goldschmidt,Hang Quach,Mohamad Mohty,Christopher P. Venner,Katja Weisel,Noopur Raje,Benjamin Hebraud,Karim Belhadj-Merzoug,Lotfi Benboubker,Olivier Decaux,Salomon Manier,Denis Caillot,Jon Ukropec,Huiling Pei,Rian Van Rampelbergh,Clarissa M. Uhlar,Rachel Kobos,Sonja Zweegman +27 more
TL;DR: In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) as mentioned in this paper .
Journal ArticleDOI
Baseline bone involvement in multiple myeloma – a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients
Maja Hinge,Kristian Thidemann Andersen,Thomas Lund,Henrik B Jørgensen,Paw Christian Holdgaard,Tina Ormstrup,Lone Lange Østergaard,Torben Plesner +7 more
TL;DR: Low-dose computed tomography scan has recently been recommended as a replacement of conventional X-ray for the diagnosis of osteolytic lesions by the European Myeloma Network.